OncoMed Pharmaceuticals, Inc. (OMED) Reaches $2.83 After 4.00% Down Move; Route One Investment Company LP Boosted By $12.04 Million Its Liberty Global Plc (LBTYA) Holding

May 17, 2018 - By Hazel Jackson

Liberty Global plc (NASDAQ:LBTYA) Logo

The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is a huge mover today! The stock decreased 5.20% or $0.15 during the last trading session, reaching $2.83. About 86,454 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since May 17, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.The move comes after 8 months negative chart setup for the $108.57M company. It was reported on May, 17 by Barchart.com. We have $2.72 PT which if reached, will make NASDAQ:OMED worth $4.34M less.

Route One Investment Company Lp increased Liberty Global Plc (LBTYA) stake by 4.49% reported in 2017Q4 SEC filing. Route One Investment Company Lp acquired 344,000 shares as Liberty Global Plc (LBTYA)’s stock declined 8.90%. The Route One Investment Company Lp holds 8.01 million shares with $286.96M value, up from 7.66 million last quarter. Liberty Global Plc now has $22.93 billion valuation. The stock decreased 1.13% or $0.34 during the last trading session, reaching $29.2. About 1.50 million shares traded. Liberty Global plc (NASDAQ:LBTYA) has declined 8.85% since May 17, 2017 and is downtrending. It has underperformed by 20.40% the S&P500.

More notable recent Liberty Global plc (NASDAQ:LBTYA) news were published by: Nasdaq.com which released: “Vodafone Group Plc Shares Fall as CEO Prepares to Step Down” on May 15, 2018, also Streetinsider.com with their article: “Glenview Capital Enters AmerisourceBergen (ABC), Express Scripts (ESRX), T-Mobile (TMUS) (more…) -13F” published on May 15, 2018, Streetinsider.com published: “End of an era as Vodafone boss Colao hands over to protege Read” on May 15, 2018. More interesting news about Liberty Global plc (NASDAQ:LBTYA) were released by: Seekingalpha.com and their article: “Liberty Global’s (LBTYA) CEO Mike Fries on Q1 2018 – Earnings Call Transcript” published on May 09, 2018 as well as Streetinsider.com‘s news article titled: “Buffett’s Berkshire 13F Confirms Increase in Apple (AAPL) Stake Along with Increase in Holdings of Teva (TEVA) (More…)” with publication date: May 15, 2018.

Among 16 analysts covering Liberty Global (NASDAQ:LBTYA), 15 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Liberty Global had 55 analyst reports since August 6, 2015 according to SRatingsIntel. As per Wednesday, March 30, the company rating was maintained by Barclays Capital. The rating was maintained by Pivotal Research with “Buy” on Friday, June 24. RBC Capital Markets maintained Liberty Global plc (NASDAQ:LBTYA) rating on Friday, April 20. RBC Capital Markets has “Buy” rating and $4300 target. The firm earned “Neutral” rating on Wednesday, May 24 by Credit Suisse. As per Friday, January 15, the company rating was maintained by Pivotal Research. The stock of Liberty Global plc (NASDAQ:LBTYA) has “Outperform” rating given on Thursday, January 14 by RBC Capital Markets. The company was maintained on Friday, October 2 by Goldman Sachs. The rating was maintained by Pivotal Research with “Buy” on Friday, January 27. The stock of Liberty Global plc (NASDAQ:LBTYA) earned “Outperform” rating by RBC Capital Markets on Monday, November 9. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, August 7 report.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on August, 1. They expect $-0.22 EPS, up 45.00% or $0.18 from last year’s $-0.4 per share. After $-0.15 actual EPS reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 46.67% negative EPS growth.

Investors sentiment increased to 1.62 in 2017 Q4. Its up 0.91, from 0.71 in 2017Q3. It improved, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Schwab Charles Investment Mngmt Inc owns 55,097 shares. Geode Mngmt Ltd Liability Corp reported 117,330 shares stake. 2,019 are held by Burt Wealth. Hodges reported 15,592 shares or 0% of all its holdings. Manufacturers Life Ins The holds 768 shares. Bridgeway Mngmt Inc reported 80,900 shares. Millennium Limited Liability Corporation holds 543,335 shares or 0% of its portfolio. Ameriprise Fin Incorporated owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 961,137 shares. Moreover, Natl Bank Of New York Mellon Corporation has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 28,707 shares. Alpine Glob Mngmt Limited Liability Com holds 18,701 shares. Tudor Invest Et Al accumulated 40,795 shares. Jacobs Levy Equity Mngmt Inc holds 48,400 shares. Citigroup invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Vanguard Gru Inc has 998,147 shares. Deutsche Bank & Trust Ag reported 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED).

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $108.57 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Since April 24, 2018, it had 0 insider purchases, and 5 insider sales for $58,301 activity. Lewicki John A. sold $12,202 worth of stock. 5,062 OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares with value of $13,555 were sold by Li Yvonne. On Tuesday, April 24 the insider Gurney Austin sold $10,848. Another trade for 4,051 shares valued at $10,848 was made by Stagg Robert on Tuesday, April 24. Another trade for 4,051 shares valued at $10,848 was sold by Hager Alicia J..

More important recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Globenewswire.com which released: “OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights” on May 08, 2018, also Nasdaq.com published article titled: “OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018”, Investorplace.com published: “3 Biotech Stocks That Will Thrive Amid Market Instability” on April 19, 2018. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) was released by: Streetinsider.com and their article: “OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR” with publication date: April 18, 2018.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts